Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma

Phase 1 Completed Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins National Cancer Institute (NCI) · collab

NaSingle-groupTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of temozolomide plus irinotecan in treating patients who have recurrent malignant glioma.

Timeline

Start: 2001-01-05
Primary completion: 2005-01-10
Completion: 2007-12-01

Publications

Results Loghin ME, Prados MD, Wen P, Junck L, Lieberman F, Fine H, Fink KL, Metha M, Kuhn J, Lamborn K, Chang SM, Cloughesy T, DeAngelis LM, Robins IH, Aldape KD, Yung WK. Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study. Clin Cancer Res. 2007 Dec 1;13(23):7133-8. doi: 10.1158/1078-0432.CCR-07-0874.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Irinotecan	Small molecule	350 mg/m2	Intravenous
Subject	Irinotecan	Small molecule	400 mg/m2	Intravenous
Subject	Irinotecan	Small molecule	450 mg/m2	Intravenous
Subject	Irinotecan	Small molecule	500 mg/m2	Intravenous
Subject	Irinotecan	Small molecule	550 mg/m2	Intravenous
Subject	Temozolomide	Small molecule	150 mg/m2	Oral

Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma

Summary

Timeline

Publications

Drugs

Indications